US biotechnology company 22nd Century Group, Inc. has completed the sale of its cannabis business, reducing future operating expenses.
According to a report by Marketscreener on December 28, the American biotechnology company, 22nd Century Group, Inc., has announced the completion of the sale transaction for its cannabis business. This transaction will significantly reduce the company’s operating expenses in the future and is a crucial step towards achieving positive cash flow.
